Sarcopenia
Conditions
Keywords
Sarcopenia, Physical capacity, Muscle force, Muscle quality, Milk proteins, Essential amino acids, Proteins, Resistance training, Exercise
Brief summary
This project evaluates the use of different types of proteins from various food sources after an exercise session, on muscle mass and physical capacity in aged sarcopenic men (who have low muscle mass). Specifically, researchers want to: * Examine the efficiency of protein intake after exercise on muscle mass and physical abilities; * Examine the impact of exercise and proteins on blood lipids (LDL cholesterol, HDL cholesterol, total cholesterol and triglycerides); * Examine the impact of exercise and proteins on liver enzymes; * Examine the impact of exercise and proteins on a hormone that controls hunger; * Evaluate the program's impact on the ability of the body to produce energy. All participants are exercising (resistance training) and ingest one of the 3 different sources of proteins, immediately after training: * Milk proteins (from milk beverage) * Essential amino acids (added to a soya beverage) * No protein (rice beverage - control group) Our hypothesis is that proteins from milk will induce a gain in muscle mass and physical function equivalent to the essential amino acids (EAA). We anticipate that both milk proteins and EAA will be both superior to control group. This would represent an interesting finding since milk is more accessible, palatable and cheaper than essential amino acids commercial mix.
Interventions
OTHERResistance training
All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
Sponsors
Dairy Farmers of Canada
Université de Sherbrooke
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
65 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* 65-75 years * francophone or understanding French * muscle mass index \< 10.75 kg/m2 (Janssen et al, 2004) * body mass index \<30kg/m² * weight stable (\< 2 kg) for 6 mo * no resistance exercise for 3 years * controlled blood pressure for at least 6 months
Exclusion criteria
* major physical disability * medical treatment influencing metabolism * statin treatment * diagnosis or any sign of kidney disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Muscle mass | At baseline and post intervention (17th week) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relative strength | At baseline and post intervention (17th week) | — |
| Blood markers of inflammation | At baseline and post intervention (17th week) | Plasmatic IL-6 anf TNF-alpha |
| Plasma Lipid profile | At baseline and post intervention (17th week) | Apolipoproteins (Apo-AI, Apo-AII, Apo-B); Total cholesterol, HDL, LDL and triglycerides. |
| Blood markers of fatty liver | At baseline and post intervention (17th week) | Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-glutamyltransferase (GGT) and Alkaline phosphatase (ALP). |
| extracellular HSP72 | At baseline and post intervention (17th week) | — |
| Plasma creatinine | At baseline, mid (8th week) and post intervention (17th week) | Blood marker on renal function will be assessed to ensure the safety of the supplementation of protein intake on renal function in sarcopenic men. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Dietary intakes | At baseline, mid (8th week) and post intervention (17th week) | 3-day food record - Control variable (in order to verify if changes we observe through the intervention are accountable or not for dietary intakes) |
| Physical activity level | At baseline and post intervention (17th week) | Physical Activity Scale for the Elderly (PASE) - Control variable (in order to verify if changes we observe through the intervention are accountable or not for daily physical activity level) |
Countries
Canada
Outcome results
None listed